Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma -

Status Active, not recruiting

Clinical Trial Summary

The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.

Clinical Trial Description

This is a single arm open label phase 1b clinical trial assessing the safety and efficacy of neoadjuvant zoledronic acid in patients with resectable any grade chondrosarcoma as measured by pathological characteristics and recurrence free survival. Prior to surgery, subjects will receive 1 standard dose of IV zoledronic acid given over 15 minutes. Surgery will be performed 21-31 days after the dose as per standard of care. The second standard dose of zoledronic acid will be given 3 weeks after surgery. Phase 1b: The Phase 1b portion of this study is to ensure the safety and tolerability of standard dose of zoledronic acid intravenously as assessed by incidence of dose limiting toxicities (DLT). Although the safety of use of this drug has been established in patients with bone metastases from solid tumors (breast, prostate) and in patients with hypercalcemia of malignancy and multiple myeloma, it has not been tested in patients with chondrosarcoma. Surgery will be performed between day 21 to 31 from the dose of zoledronic acid to allow its effect on the tumor and resolution of toxicities. A total of 6 patients will be enrolled in this run-in phase 1b. Patients will be followed post operatively as per NCCN guidelines (for years 1 and 2) with local and systemic imaging. Expansion Cohort: The phase 1 b expansion cohort of the study will provide an estimate of the relative treatment effect of zoledronic acid on any grade chondrosarcoma specimens. Subjects will receive a total of 2 doses of zoledronic acid, one dose prior to surgery and the second dose 21 days after surgery. Patients will undergo standard of care surgery 21-31 days from the first dose of zoledronic acid. 9 subjects will be enrolled in this cohort for a total of 15 planned subject enrollment over 3 years. Patients will be followed post operatively for recurrence with imaging and survival and as per NCCN guidelines (for years 1 and 2). ;

Study Design

Related Conditions & MeSH terms

Chondrosarcoma

Clinical Trial Details

NCT number	NCT03173976
Study type	Interventional
Source	University of Iowa
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	July 18, 2017
Completion date	July 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05039801` - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	Phase 1
Recruiting	`NCT04553692` - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers	Phase 1
Recruiting	`NCT06029218` - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy	N/A
Recruiting	`NCT04040205` - Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration	Phase 2
Not yet recruiting	`NCT06029478` - Understanding Engagement Trends in Chondrosarcoma Clinical Trials
Completed	`NCT01553539` - Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00004241` - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Phase 1
Active, not recruiting	`NCT04521686` - Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	Phase 1
Recruiting	`NCT03715933` - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Phase 1
Completed	`NCT02496741` - Metformin And Chloroquine in IDH1/2-mutated Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Terminated	`NCT00543712` - A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)	Phase 2
Recruiting	`NCT05861245` - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	N/A
Completed	`NCT00464620` - Trial of Dasatinib in Advanced Sarcomas	Phase 2
Recruiting	`NCT04278781` - AG-120 in People With IDH1 Mutant Chondrosarcoma	Phase 2
Recruiting	`NCT04055220` - Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	N/A
Recruiting	`NCT04673942` - A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors	Phase 2
Completed	`NCT01560260` - Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Phase 2
Completed	`NCT01609179` - IPI-926 Extension Protocol for Continuation of Treatment With IPI-926	N/A
Recruiting	`NCT06387485` - A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms